Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Trial Profile

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ONSET 2
  • Sponsors Novo Nordisk; Novo Nordisk Pharma
  • Most Recent Events

    • 08 Dec 2017 Results of a post-hoc analysis from Onset-2 and Onset-3 studies, presented at the 2017 Congress of the International Diabetes Federation
    • 08 Dec 2017 Results of post-hoc, subgroup analysis assessing the effect of fast-acting insulin aspart on postprandial plasma glucose control in individuals with T2D receiving high doses of bolus insulin, presented at the 2017 Congress of the International Diabetes Federation.
    • 29 Sep 2017 According to a Novo Nordisk media release, the US FDA has approved Fiasp for glycemic control in adults with tyep1 and type 2 diabetes based on data from this and other three trials (231999, 232775, 238002 trials from ONSET programme).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top